Comparative Pharmacology
Head-to-head clinical analysis: KLEBCIL versus VEETIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLEBCIL versus VEETIDS.
KLEBCIL vs VEETIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
VEETIDS (generic: voretigene neparvovec) is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
500 mg orally twice daily for 7-14 days.
None Documented
None Documented
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; extends to 6-10 hours in moderate renal impairment.
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Renal elimination (60-80% unchanged); biliary/fecal excretion accounts for 15-20%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic